AMRN Quote, Financials, Valuation and Earnings

Jazz Pharmaceuticals PLC has a net margin of -37.36% compared to Amarin Corp PLC's net margin of -10.31%. Amarin Corp PLC's return on equity of -16.98% beat Jazz Pharmaceuticals PLC's return on equity of 12.12%.

Amarin Corp PLC has a consensus price target of $8.00, signalling downside risk potential of -35.12%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $188.63 which suggests that it could grow by 68.61%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Amarin Corp PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Amarin Corp PLC.

Amarin Corp PLC has a beta of 0.713, which suggesting that the stock is 28.745% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.327, suggesting its less volatile than the S&P 500 by 67.347%.

Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Amarin Corp PLC quarterly revenues are $42M, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $897.8M. Amarin Corp PLC's net income of -$15.7M is higher than Jazz Pharmaceuticals PLC's net income of -$92.5M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Jazz Pharmaceuticals PLC's PE ratio is 14.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 1.19x versus 1.76x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic PLC has a net margin of -37.36% compared to Amarin Corp PLC's net margin of 11.84%. Amarin Corp PLC's return on equity of -16.98% beat Medtronic PLC's return on equity of 9.51%.

Amarin Corp PLC has a consensus price target of $8.00, signalling downside risk potential of -35.12%. On the other hand Medtronic PLC has an analysts' consensus of $95.43 which suggests that it could grow by 9.13%. Given that Medtronic PLC has higher upside potential than Amarin Corp PLC, analysts believe Medtronic PLC is more attractive than Amarin Corp PLC.

Amarin Corp PLC has a beta of 0.713, which suggesting that the stock is 28.745% less volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.747%.

Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic PLC offers a yield of 3.2% to investors and pays a quarterly dividend of $0.70 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Medtronic PLC pays out 76.98% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amarin Corp PLC quarterly revenues are $42M, which are smaller than Medtronic PLC quarterly revenues of $8.9B. Amarin Corp PLC's net income of -$15.7M is lower than Medtronic PLC's net income of $1.1B. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Medtronic PLC's PE ratio is 24.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 1.19x versus 3.36x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.

Perrigo Co PLC has a net margin of -37.36% compared to Amarin Corp PLC's net margin of -0.61%. Amarin Corp PLC's return on equity of -16.98% beat Perrigo Co PLC's return on equity of -4.01%.

Amarin Corp PLC has a consensus price target of $8.00, signalling downside risk potential of -35.12%. On the other hand Perrigo Co PLC has an analysts' consensus of $36.50 which suggests that it could grow by 39.47%. Given that Perrigo Co PLC has higher upside potential than Amarin Corp PLC, analysts believe Perrigo Co PLC is more attractive than Amarin Corp PLC.

Amarin Corp PLC has a beta of 0.713, which suggesting that the stock is 28.745% less volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.43%.

Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co PLC offers a yield of 4.33% to investors and pays a quarterly dividend of $0.29 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Perrigo Co PLC pays out -88.77% of its earnings as a dividend.

Amarin Corp PLC quarterly revenues are $42M, which are smaller than Perrigo Co PLC quarterly revenues of $1B. Amarin Corp PLC's net income of -$15.7M is lower than Perrigo Co PLC's net income of -$6.4M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 1.19x versus 0.83x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech PLC has a net margin of -37.36% compared to Amarin Corp PLC's net margin of -31.41%. Amarin Corp PLC's return on equity of -16.98% beat Trinity Biotech PLC's return on equity of --.

Amarin Corp PLC has a consensus price target of $8.00, signalling downside risk potential of -35.12%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 2190.43%. Given that Trinity Biotech PLC has higher upside potential than Amarin Corp PLC, analysts believe Trinity Biotech PLC is more attractive than Amarin Corp PLC.

Amarin Corp PLC has a beta of 0.713, which suggesting that the stock is 28.745% less volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 0.840, suggesting its less volatile than the S&P 500 by 15.99%.

Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.

Amarin Corp PLC quarterly revenues are $42M, which are larger than Trinity Biotech PLC quarterly revenues of $15.2M. Amarin Corp PLC's net income of -$15.7M is lower than Trinity Biotech PLC's net income of -$4.8M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 1.19x versus 0.13x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.